Two device recalls in under 60 days. A reported-injury count that exploded from 18 to 476. A securities class action filed just 17 days ago in federal court. And personal injury attorneys now actively investigating wrongful death claims on behalf of patients who suffered diabetic ketoacidosis, coma, or worse. The OmniPod 5 lawsuit landscape is moving fast — and for the millions of Type 1 diabetics who depend on Insulet’s tubeless patch pump, the stakes could not be higher.
What Is the OmniPod 5 and Why Does the Defect Matter?
The OmniPod 5 is a tubeless, wearable automated insulin delivery system manufactured by Insulet Corporation and used widely by people living with Type 1 diabetes. Unlike traditional insulin pumps, the OmniPod is a patch pump — meaning there is no external tubing connecting the pump body to the cannula inserted under the skin. Insulin flows entirely through internal components sealed inside a small, disposable pod worn directly on the body.
That design feature, which is central to OmniPod’s appeal, is also what makes the recalled defect so dangerous. When internal tubing tears inside the pod, insulin leaks within the device instead of entering the patient’s body. Because there is no external tubing to inspect and no visible sign of failure, users have no way to detect under-delivery without a device alert — and those alerts did not reliably trigger. A patient believing they are receiving their full insulin dose may instead be receiving none, silently drifting toward a life-threatening metabolic crisis.
The Centers for Disease Control and Prevention reports that approximately 2 million Americans live with Type 1 diabetes — a population almost entirely dependent on continuous insulin delivery. Any systemic failure in delivery technology carries mass-harm potential that extends far beyond a single patient.
The 2026 OmniPod Recalls: A Timeline of Escalating Failures
March 12, 2026: The First Recall and 18 Known Injuries
On March 12, 2026, Insulet Corporation issued a voluntary Medical Device Correction for certain OmniPod 5 pods after the company discovered a manufacturing defect — specifically, a small tear in internal tubing that causes insulin to leak inside the pod rather than being delivered to the patient. The result is under-delivery of insulin, a condition that can rapidly escalate into a metabolic emergency.
Six days later, on March 18, 2026, the U.S. Food and Drug Administration issued its own public safety alert warning that malfunctions associated with the defect could cause diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state, coma, and death. At the time of the March recall, Insulet had identified 18 serious adverse events linked to the manufacturing defect. Insulet’s stock fell $16.23 per share — a drop of 6.88% — following the March 13 announcement, closing at $219.84. Investors were shaken. Patients were alarmed. But the worst was still coming.
April 30 to May 2026: Injuries Surge, Second Recall Issued
On April 30, 2026, Insulet announced an expanded removal from use after the reported serious adverse event count surged from 18 to 476 in roughly 45 days — a more than 26-fold increase in under two months. This figure represents known reports and almost certainly undercounts actual harm, as patients who experienced under-delivery and recovered without hospitalization may not have attributed the event to a device failure.
Then in May 2026, Insulet issued a second, broader recall — this time involving certain OmniPod 5, OmniPod DASH, and original OmniPod Eros pods. The May recall identified a defect capable of damaging the tubing used to deliver insulin, extending the scope of risk beyond the single product line affected in March. For patients and attorneys tracking the OmniPod 5 lawsuit story, the May recall confirmed what the injury data had already suggested: this was not an isolated quality-control incident but a systemic manufacturing failure across Insulet’s product portfolio.
| Event | Date | Key Detail |
|---|---|---|
| First Voluntary Medical Device Correction | March 12, 2026 | Internal tubing tear; insulin under-delivery; 18 serious adverse events reported |
| FDA Public Safety Alert | March 18, 2026 | Warned of DKA, hyperosmolar hyperglycemic state, coma, and death risk |
| Insulet Stock Drop | March 13, 2026 | Fell $16.23/share (6.88%); closed at $219.84 |
| Expanded Removal Announced | April 30, 2026 | Reported injuries exploded from 18 to 476 in ~45 days |
| Second Broader Recall | May 2026 | Expanded to OmniPod DASH and OmniPod Eros; tubing damage defect |
| Securities Class Action Filed | July 2, 2026 | Filed in U.S. District Court, District of Massachusetts; class period Feb. 21, 2025 – May 26, 2026 |
The July 2, 2026 Securities Class Action: What Investors Need to Know
On July 2, 2026 — just 17 days ago — plaintiff Zhenjun Hu filed an investor class action in the U.S. District Court for the District of Massachusetts seeking class status for all investors who acquired Insulet Corporation securities between February 21, 2025, and May 26, 2026. The complaint names current CEO Ashley A. McEvoy and former CEO James R. Hollingshead as defendants.
The core allegation is that Insulet made false and misleading statements about its manufacturing controls and product quality throughout the class period — and that after the first March recall became public, the company continued to downplay the scope of its manufacturing problems and assured customers and investors that other products in its lineup were safe, even as injury reports were mounting and a second recall was imminent. If proven, these allegations could support significant shareholder recovery through the securities fraud framework established under federal law.
For investors who purchased Insulet stock during the class period and suffered losses when the recalls and expanding injury counts came to light, this action represents an early opportunity to join the litigation. Lead plaintiff deadlines in securities class actions typically run 60 days from the filing date, placing that deadline near September 1, 2026. Investors with substantial losses should document their transaction history now.
Personal Injury and Wrongful Death Investigations: What Patients and Families Need to Know
Parallel to the investor litigation, personal injury attorneys across the country began actively investigating claims in June 2026 on behalf of patients harmed by OmniPod device failures. The theories of liability under investigation include design defect, manufacturing defect, failure to warn, and quality-assurance failures — each of which represents a distinct legal pathway to recovery under product liability law.
Patients who experienced DKA, hyperosmolar hyperglycemic state, coma, or other serious complications while using OmniPod 5, OmniPod DASH, or OmniPod Eros during the relevant period may have viable personal injury claims. Families who lost a loved one to a suspected insulin under-delivery event involving a recalled pod may be entitled to pursue wrongful death claims. To understand the potential value of a claim involving a fatal device failure, families can use a wrongful death calculator as a preliminary step before consulting with legal counsel.
Critically, no Multi-District Litigation (MDL) has been formed yet as of July 19, 2026. MDL consolidation — which typically occurs after dozens or hundreds of related federal cases are filed — has not happened here. That means individual plaintiffs filing now retain more control over case strategy, discovery timing, and early settlement positioning than they would after MDL consolidation. Pre-MDL filing has historically offered strategic advantages in large device defect cases, and the window is open right now. Patients and families considering an OmniPod 5 lawsuit should take this timing seriously.
For patients trying to understand how a defective medical device injury translates into a civil claim, a medical malpractice calculator can provide general guidance on how courts and juries evaluate injury severity, economic damages, and pain and suffering in device defect contexts.
How to Document Your OmniPod Injury Claim Starting Today
If you or a family member used an OmniPod 5, OmniPod DASH, or OmniPod Eros pod during 2026 and suffered a serious adverse event, the evidence you preserve in the coming days and weeks could determine the strength of a future OmniPod 5 lawsuit claim. Here are the steps you should take immediately:
- Preserve the defective pod. Do not discard the pod you believe failed. Seal it in a clean plastic bag and label it with the lot number, serial number, and date of use. Physical evidence of the defect is critical in product liability litigation.
- Request all medical records. Obtain records from every emergency department visit, hospitalization, or provider contact related to your adverse event. DKA admissions, blood glucose logs, and any physician notes attributing the event to insulin under-delivery are highly relevant.
- File an FDA MedWatch report. Reporting your injury through the FDA MedWatch Adverse Event Reporting Program creates an official public record of your experience and contributes to the regulatory pressure that can accelerate litigation and settlement.
- Document financial losses. Save records of all out-of-pocket medical costs, lost wages, and any costs associated with transitioning to alternative insulin delivery systems following the recall.
- Contact legal counsel promptly. Statutes of limitations for product liability claims vary by state. Waiting too long can permanently bar your right to file. The pre-MDL period is the optimal time to enter this litigation.
Understanding the general range of personal injury compensation in defective device cases can help claimants have more informed conversations with attorneys. A personal injury settlement calculator can provide a broad estimate based on injury type, medical costs, and other factors — though actual recovery depends on the specific facts of each case.
Frequently Asked Questions About the OmniPod 5 Lawsuit
Who is eligible to file an OmniPod 5 lawsuit?
Patients who used a recalled OmniPod 5, OmniPod DASH, or OmniPod Eros pod during 2026 and suffered a serious adverse event — including DKA, hyperosmolar hyperglycemic state, coma, hospitalization, or death — may be eligible to file a personal injury or wrongful death lawsuit against Insulet Corporation. Eligibility depends on whether the pod used was subject to either the March 2026 or May 2026 recall, the severity of the injury suffered, and applicable state statute of limitations deadlines. Investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, and suffered stock losses may also be eligible to join the securities class action filed on July 2, 2026.
What injuries are linked to the OmniPod defect?
The FDA’s March 18, 2026 public safety alert identified diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state, coma, and death as potential outcomes of the insulin under-delivery caused by the internal tubing defect. DKA is a life-threatening condition caused by a severe lack of insulin that forces the body to break down fat at a dangerous rate, producing toxic acids. Hyperosmolar hyperglycemic state is a similarly dangerous condition characterized by extremely high blood sugar, dehydration, and altered consciousness. Both conditions require emergency hospitalization and can cause lasting organ damage even in survivors.
Has an MDL been formed for OmniPod lawsuits yet?
As of July 19, 2026, no Multi-District Litigation (MDL) proceeding has been established for OmniPod personal injury or wrongful death claims. The litigation is at its earliest pre-MDL stage. This is significant for potential claimants because filing before MDL consolidation can offer strategic advantages, including more individual control over case strategy and positioning for early resolution. The securities class action filed on July 2, 2026, is a separate proceeding in U.S. District Court for the District of Massachusetts and follows its own procedural track distinct from personal injury claims.
What is Insulet accused of in the securities class action?
The July 2, 2026 securities class action filed by plaintiff Zhenjun Hu alleges that Insulet Corporation, current CEO Ashley A. McEvoy, and former CEO James R. Hollingshead made false and misleading statements to investors about the company’s manufacturing controls and product quality during the class period of February 21, 2025, through May 26, 2026. Specifically, the complaint alleges that after the first March 2026 recall became public, Insulet continued to downplay the scope of its manufacturing problems and falsely assured investors and customers that other products were safe — even as reported injuries were surging from 18 to 476 and a second recall was imminent. Investors who suffered losses during the class period may be entitled to recovery.
How long do I have to file an OmniPod 5 lawsuit?
The deadline to file an OmniPod 5 personal injury or wrongful death lawsuit depends on your state’s statute of limitations for product liability claims, which typically ranges from two to four years from the date of injury or the date you reasonably discovered the injury was caused by the device. Because the recalls occurred in early-to-mid 2026, many state clocks are running now. For the securities class action, lead plaintiff applications are generally due 60 days after the initial filing, placing a deadline around September 1, 2026, for investors seeking to lead the class. Consulting with an attorney as soon as possible is strongly advised to protect your rights before any applicable deadline expires.
This article is provided for general informational purposes only and does not constitute legal advice; individuals seeking guidance about a specific legal situation should consult a licensed attorney in their jurisdiction.
Related reading: Vascular Surgery Malpractice Settlement Amounts: 2026 Data, Verdicts & How Compensation Is Calculated
Related reading: $104 Million Verdict: How Ghost Gun Wrongful Death Damages Are Calculated When A Seller Bypasses Federal Age Laws
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.